Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / SYRS - Syros Pharmaceuticals Is A Buy As New Trials Start

SYRS - Syros Pharmaceuticals Is A Buy As New Trials Start

Syros Pharmaceuticals Inc.
  • Tamibarotene Phase 2 AML data is expected in 2022.
  • Positive trial AML or MDS data would lead to an application to the FDA in 2024.
  • Expanded trials for SY-5609 are getting underway.

For further details see:

Syros Pharmaceuticals Is A Buy As New Trials Start
Stock Information
Company Name: Syros Pharmaceuticals Inc.
Stock Symbol: SYRS
Market: NASDAQ
Website: syros.com
Menu
SYRS SYRS Quote SYRS Short SYRS News SYRS Articles SYRS Message Board
Get SYRS Alerts

News, Short Squeeze, Breakout and More Instantly...